Enterprise League logo
V

ViImmune

Irvine, United States (US) · Health and Medical

We built this page from public sources. What we do with your data

Do you work at ViImmune?

Claim this profile to manage your company.

Verified by Enterprise League

Data quality

Complete · Accuracy

ViImmune is a US-based biopharmaceutical company specializing in the development of novel, long-acting anti-HIV agents.We are focused on leveraging previously discovered compounds to create dual-action antiviral agents designed to combat HIV infection with enhanced efficacy and a prolonged duration of action.

Overview

ViImmune is a US-based biopharmaceutical company specializing in the development of novel, long-acting anti-HIV agents.

We are focused on leveraging previously discovered compounds to create dual-action antiviral agents designed to combat HIV infection with enhanced efficacy and a prolonged duration of action. Our approach utilizes sustained intracellular release of active substrates, minimizing the risk of viral resistance development.

ViImmune’s research and development efforts are centered around improving existing antiviral therapies and creating a more effective treatment landscape for individuals living with HIV. We are dedicated to advancing innovative solutions within the biotechnology research sector, contributing to a future with more manageable and sustainable HIV treatment options.

ViImmune’s technology is protected by multiple patents, demonstrating a strong foundation for continued growth and development.
Visit Official Website

Most teams do this before shortlisting


Contact Details

info@viimmune.com

Irvine, United States (US), 5270 California Ave

Company Type

Private Limited Company

Employees

2-10

Categories

Biopharma
Life Science
Biotechnology

Awards

• 2026 OpenSee all

Products

Default Product Image
Long-Acting Anti-HIV Agents
Biotechnology

ViImmune is developing a new generation of long-acting anti-HIV agents designed to provide sustained antiviral activity and reduce the frequency of dosing. These agents utilize a dual-action mechanism to target multiple stages of the HIV life cycle, minimizing the risk of resistance.

N/A

Companies teams usually look at after ViImmune

Comparing a few options usually leads to better decisions






  • Save companies to compare later. Useful when sharing options with your team

This is how your company profile looks to others.